journal
MENU ▼
Read by QxMD icon Read
search

Cardiovascular Diabetology

journal
https://www.readbyqxmd.com/read/28327146/association-between-obstructive-sleep-apnea-severity-and-endothelial-dysfunction-in-patients-with-type-2-diabetes
#1
Vanessa Bironneau, François Goupil, Pierre Henri Ducluzeau, Marc Le Vaillant, Pierre Abraham, Samir Henni, Séverine Dubois, Audrey Paris, Pascaline Priou, Nicole Meslier, Claire Sanguin, Wojciech Trzépizur, Ramaroson Andriantsitohaina, Maria Carmen Martinez, Frédéric Gagnadoux
BACKGROUND: Obstructive sleep apnea (OSA) and type 2 diabetes (T2D) are associated with endothelial dysfunction a main predictor of late cardiovascular (CV) events. Despite the high prevalence of OSA in patients with T2D, the impact of OSA severity on endothelial function has not been clearly elucidated. The aim of this cross-sectional study was to determine whether increasing OSA severity is associated with poorer endothelial function in patients with T2D. METHODS: 140 patients with T2D and no overt CV disease underwent polysomnography, peripheral arterial tonometry, clinic blood pressure (BP) measurement, biological assessment for CV risk factors, daytime sleepiness and health related quality of life (HRQL) questionnaires...
March 21, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28327140/efficacy-and-safety-of-canagliflozin-in-patients-with-type-2-diabetes-based-on-history-of-cardiovascular-disease-or-cardiovascular-risk-factors-a-post-hoc-analysis-of-pooled-data
#2
Michael J Davies, Katherine Merton, Ujjwala Vijapurkar, Jacqueline Yee, Rong Qiu
BACKGROUND: Treatment of patients with type 2 diabetes mellitus (T2DM) and a history of cardiovascular (CV) disease or CV risk factors may present clinical challenges due to the presence of comorbid conditions and the use of concomitant medications. The sodium glucose co-transporter 2 inhibitor, canagliflozin, has been shown to improve glycaemic control and reduce body weight and blood pressure (BP) with a favourable tolerability profile in a broad range of patients with T2DM. This post hoc analysis assessed the efficacy and safety of canagliflozin in patients with T2DM based on CV disease history or CV risk factors...
March 21, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28320383/lipoprotein-a-and-incident-type-2-diabetes-results-from-the-prospective-bruneck-study-and-a-meta-analysis-of-published-literature
#3
Ellie Paige, Katya L Masconi, Sotirios Tsimikas, Florian Kronenberg, Peter Santer, Siegfried Weger, Johann Willeit, Stefan Kiechl, Peter Willeit
AIMS: We aimed to (1) assess the association between lipoprotein(a) [Lp(a)] concentration and incident type-2 diabetes in the Bruneck study, a prospective population-based study, and (2) combine findings with evidence from published studies in a literature-based meta-analysis. METHODS: We used Cox proportional hazards models to calculate hazard ratios (HR) for incident type-2 diabetes over 20 years of follow-up in 815 participants of the Bruneck study according to their long-term average Lp(a) concentration...
March 21, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28292300/clinical-outcomes-and-glycaemic-responses-to-different-aerobic-exercise-training-intensities-in-type-ii-diabetes-a-systematic-review-and-meta-analysis
#4
Aimee Grace, Erick Chan, Francesco Giallauria, Petra L Graham, Neil A Smart
AIMS: To establish if aerobic exercise training is associated with beneficial effects on clinical outcomes and glycaemic profile in people with type II diabetes. METHODS: A systematic search was conducted to identify studies through a search of MEDLINE (1985 to Sept 1, 2016, Cochrane Controlled Trials Registry (1966 to Sept 1, 2016), CINAHL, SPORTDiscus and Science Citation Index. The search strategy included a mix of MeSH and free text terms for related key concepts...
March 14, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28292297/subclinical-left-ventricular-diastolic-dysfunction-and-incident-type-2-diabetes-risk-the-korean-genome-and-epidemiology-study
#5
Juri Park, Jin-Seok Kim, Seong Hwan Kim, Sunwon Kim, Sang Yup Lim, Hong-Euy Lim, Goo-Yeong Cho, Ki-Chul Sung, Jang-Young Kim, Inkyung Baik, Kwang Kon Koh, Jung Bok Lee, Seung Ku Lee, Chol Shin
BACKGROUND: Subclinical left ventricular (LV) diastolic dysfunction in type 2 diabetes (T2D) is a common finding and represents an early sign of diabetic cardiomyopathy. However, the relationship between LV diastolic dysfunction and the incident T2D has not been previously studied. METHODS: A total of 1817 non-diabetic participants (mean age, 54 years; 48% men) from the Korean Genome and Epidemiology Study who were free of cardiovascular disease were studied. LV structure and function were assessed by conventional echocardiography and tissue Doppler imaging...
March 14, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28284218/report-from-the-2nd-cardiovascular-outcome-trial-cvot-summit-of-the-diabetes-and-cardiovascular-disease-d-cvd-easd-study-group
#6
EDITORIAL
Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Stefano Genovese, Nebojsa Lalic, Jan Skra, Paul Valensi, Dario Rahelic, Antonio Ceriello
The 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group was held on the 20th-21st October 2016 in Munich. This second Summit was organized in light of recently published CVOTs on diabetes, with the aim of serving as a reference meeting for discussion on this topic. Along with presentations on the results of the most recently published CVOTs, panel discussions on trial implications for reimbursement and the perspective of cardiologists and/or nephrologists, as well as on CVOTs weaknesses and potentials constituted the heart of the program...
March 11, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28279217/hypofibrinolysis-in-diabetes-a-therapeutic-target-for-the-reduction-of-cardiovascular-risk
#7
REVIEW
Katherine Kearney, Darren Tomlinson, Kerrie Smith, Ramzi Ajjan
An enhanced thrombotic environment and premature atherosclerosis are key factors for the increased cardiovascular risk in diabetes. The occlusive vascular thrombus, formed secondary to interactions between platelets and coagulation proteins, is composed of a skeleton of fibrin fibres with cellular elements embedded in this network. Diabetes is characterised by quantitative and qualitative changes in coagulation proteins, which collectively increase resistance to fibrinolysis, consequently augmenting thrombosis risk...
March 9, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28253918/luseogliflozin-reduces-epicardial-fat-accumulation-in-patients-with-type-2-diabetes-a-pilot-study
#8
Ryotaro Bouchi, Masahiro Terashima, Yuriko Sasahara, Masahiro Asakawa, Tatsuya Fukuda, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto, Yoshihiro Ogawa
BACKGROUND: Accumulation of epicardial fat (EF) is associated with increased cardio-metabolic risks and coronary events, independently of traditional cardiovascular risk factors. Therefore, the reduction of EF volume (EFV) may be associated with reduced cardio-metabolic risks and future cardiovascular events. Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce body fat including visceral fat and cardiovascular events in patients with type 2 diabetes. However, it has still been unknown whether SGLT2 inhibitors can reduce EFV...
March 3, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28253885/the-nuclear-factor-erythroid-derived-2-like-2-nrf2-activator-dh404-protects-against-diabetes-induced-endothelial-dysfunction
#9
Arpeeta Sharma, Luddwi Rizky, Nada Stefanovic, Mitchel Tate, Rebecca H Ritchie, Keith W Ward, Judy B de Haan
BACKGROUND: Vascular dysfunction is a pivotal event in the development of diabetes-associated vascular disease. Increased inflammation and oxidative stress are major contributors to vascular dysfunction. Nrf2, a master regulator of several anti-oxidant genes and a suppressor of inflammatory NF-κB, has potential as a target to combat oxidative stress and inflammation. The aim of this study was to investigate the effects of a novel Nrf2 activator, the bardoxolone methyl derivative dh404, on endothelial function in vitro and in vivo...
March 3, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28249585/incretin-based-agents-in-type-2-diabetic-patients-at-cardiovascular-risk-compare-the-effect-of-glp-1-agonists-and-dpp-4-inhibitors-on-cardiovascular-and-pancreatic-outcomes
#10
Zeqing Zhang, Xi Chen, Puhan Lu, Jianhua Zhang, Yongping Xu, Wentao He, Mengni Li, Shujun Zhang, Jing Jia, Shiying Shao, Junhui Xie, Yan Yang, Xuefeng Yu
BACKGROUND: Incretin-based agents, including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 agonists (GLP-1As), work via GLP-1 receptor for hyperglycemic control directly or indirectly, but have different effect on cardiovascular (CV) outcomes. The present study is to evaluate and compare effects of incretin-based agents on CV and pancreatic outcomes in patients with type 2 diabetes mellitus (T2DM) and high CV risk. METHODS: Six prospective randomized controlled trials (EXMAINE, SAVOR-TIMI53, TECOS, ELIXA, LEADER and SUSTAIN-6), which included three trials for DPP-4Is and three trials for GLP-1As, with 55,248 participants were selected to assess the effect of different categories of incretin-based agents on death, CV outcomes (CV mortality, major adverse CV events, nonfatal myocardial infarction, nonfatal stroke, heart failure hospitalization), pancreatic events (acute pancreatitis and pancreatic cancer) as well as on hypoglycemia...
March 1, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28249577/cumulative-increased-risk-of-incident-type-2-diabetes-mellitus-with-increasing-triglyceride-glucose-index-in-normal-weight-people-the-rural-chinese-cohort-study
#11
Ming Zhang, Bingyuan Wang, Yu Liu, Xizhuo Sun, Xinping Luo, Chongjian Wang, Linlin Li, Lu Zhang, Yongcheng Ren, Yang Zhao, Junmei Zhou, Chengyi Han, Jingzhi Zhao, Dongsheng Hu
BACKGROUND: Risk of type 2 diabetes mellitus (T2DM) is increased in metabolically obese but normal-weight people. However, we have limited knowledge of how to prevent T2DM in normal-weight people. We aimed to evaluate the association between triglyceride glucose (TyG) index and incident T2DM among normal-weight people in rural China. METHODS: We included data from 5706 people with normal body mass index (BMI) (18.5-23.9 kg/m(2)) without baseline T2DM in a rural Chinese cohort followed for a median of 6...
March 1, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28241822/effects-of-canagliflozin-a-sodium-glucose-co-transporter-2-inhibitor-on-blood-pressure-and-markers-of-arterial-stiffness-in-patients-with-type-2-diabetes-mellitus-a-post-hoc-analysis
#12
Michael Pfeifer, Raymond R Townsend, Michael J Davies, Ujjwala Vijapurkar, Jimmy Ren
BACKGROUND: Physiologic determinants, such as pulse pressure [difference between systolic blood pressure (SBP) and diastolic BP (DBP)], mean arterial pressure (2/3 DBP + 1/3 SBP), and double product [beats per minute (bpm) × SBP], are linked to cardiovascular outcomes. The effects of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on pulse pressure, mean arterial pressure, and double product were assessed in patients with type 2 diabetes mellitus (T2DM). METHODS: This post hoc analysis was based on pooled data from four 26-week, randomized, double-blind, placebo-controlled studies evaluating canagliflozin in patients with T2DM (N = 2313) and a 6-week, randomized, double-blind, placebo-controlled, ambulatory BP monitoring (ABPM) study evaluating canagliflozin in patients with T2DM and hypertension (N = 169)...
February 27, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28231848/diagnostic-approaches-for-diabetic-cardiomyopathy
#13
REVIEW
A Lorenzo-Almorós, J Tuñón, M Orejas, M Cortés, J Egido, Ó Lorenzo
Diabetic cardiomyopathy (DCM) is a cardiac dysfunction which affects approximately 12% of diabetic patients, leading to overt heart failure and death. However, there is not an efficient and specific methodology for DCM diagnosis, possibly because molecular mechanisms are not fully elucidated, and it remains asymptomatic for many years. Also, DCM frequently coexists with other comorbidities such as hypertension, obesity, dyslipidemia, and vasculopathies. Thus, human DCM is not specifically identified after heart failure is established...
February 23, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28231835/vildagliptin-but-not-glibenclamide-increases-circulating-endothelial-progenitor-cell-number-a-12-month-randomized-controlled-trial-in-patients-with-type-2-diabetes
#14
Alessandra Dei Cas, Valentina Spigoni, Monia Cito, Raffaella Aldigeri, Valentina Ridolfi, Elisabetta Marchesi, Michela Marina, Eleonora Derlindati, Rosalia Aloe, Riccardo C Bonadonna, Ivana Zavaroni
BACKGROUND: Fewer circulating endothelial progenitor cells (EPCs) and increased plasma (C-term) stromal cell-derived factor 1α (SDF-1α), a substrate of DPP-4, are biomarkers, and perhaps mediators, of cardiovascular risk and mortality. Short-term/acute treatment with DPP-4 inhibitors improve EPC bioavailability; however, long-term effects of DPP-4i on EPCs bioavailability/plasma (C-term) SDF-1α are unknown. METHODS: Randomized (2:1) open-label trial to compare the effects of vildagliptin (V) (100 mg/day) vs glibenclamide (G) (2...
February 23, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28231831/a-randomised-study-of-the-impact-of-the-sglt2-inhibitor-dapagliflozin-on-microvascular-and-macrovascular-circulation
#15
Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V Karg, Peter Bramlage, Roland E Schmieder
BACKGROUND: The sodium-glucose cotransporter 2 inhibitor, dapagliflozin, has been shown to improve diabetic control and reduce blood pressure in patients with type 2 diabetes mellitus. Its effects on micro- and macrovascular structure and function have not yet been reported. METHODS: This was a prospective, single-centre, placebo-controlled, double-blind, randomised crossover phase IIIb study conducted between March 2014 and February 2015. After a 4-week run-in/washout phase, patients (N = 59) received 6 weeks of either dapagliflozin 10 mg or placebo once daily...
February 23, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28209202/erratum-to-inflammation-glucose-and-vascular-cell-damage-the-role-of-the-pentose-phosphate-pathway
#16
Concepción Peiró, Tania Romacho, Verónica Azcutia, Laura Villalobos, Emilio Fernández, Juan P Bolaños, Salvador Moncada, Carlos F Sánchez-Ferrer
No abstract text is available yet for this article.
February 16, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28202017/association-between-metformin-use-and-below-the-knee-arterial-calcification-score-in-type-2-diabetic-patients
#17
Aurélien Mary, Agnes Hartemann, Sophie Liabeuf, Carole Elodie Aubert, Salim Kemel, Joe Elie Salem, Philippe Cluzel, Aurélie Lenglet, Ziad A Massy, Jean-Daniel Lalau, Romuald Mentaverri, Olivier Bourron, Saïd Kamel
BACKGROUND: Vascular calcification (VC) is common in type 2 diabetes, and is associated with cardiovascular complications. Recent preclinical data suggest that metformin inhibits VC both in vitro and in animal models. However, metformin's effects in patients with diabetic VC have not previously been characterized. The present study investigated the association between metformin use and lower-limb arterial calcification in patients with type 2 diabetes and high cardiovascular risk. METHODS: The DIACART cross-sectional cohort study included 198 patients with type 2 diabetes but without severe chronic kidney disease...
February 15, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28183314/dpp-4-inhibition-has-no-acute-effect-on-bnp-and-its-n-terminal-pro-hormone-measured-by-commercial-immune-assays-a-randomized-cross-over-trial-in-patients-with-type-2-diabetes
#18
Gian Paolo Fadini, Benedetta Maria Bonora, Mattia Albiero, Martina Zaninotto, Mario Plebani, Angelo Avogaro
BACKGROUND: Use of dipeptidyl peptidase-4 inhibitors (DPP4-i) for the treatment of type 2 diabetes (T2D) has been associated with a possible increase in the risk for heart failure (HF). B-type natriuretic peptide (BNP), which is both a biomarker of HF and a hemodynamically active hormone, is a substrate of DPP-4. We herein tested the acute effects of the DPP-4i linagliptin on BNP and NT-proBNP in a cross-over placebo-controlled trial in patients with T2D with and without chronic kidney disease (CKD)...
February 10, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28183306/third-generation-drug-eluting-stent-des-with-biodegradable-polymer-in-diabetic-patients-5%C3%A2-years-follow-up
#19
Marcus Wiemer, Sinisa Stoikovic, Alexander Samol, Zisis Dimitriadis, Juan M Ruiz-Nodar, Ralf Birkemeyer, Jacques Monsegu, Gérard Finet, David Hildick-Smith, Damras Tresukosol, Enrique Garcia Novo, Jacques J Koolen, Emanuele Barbato, Gian Battista Danzi
OBJECTIVE: To report the long-term safety and efficacy data of a third generation drug eluting stent (DES) with biodegradable polymer in the complex patient population of diabetes mellitus after a follow-up period of 5 years. BACKGROUND: After percutaneous coronary intervention patients with diabetes mellitus are under higher risk of death, restenosis and stent thrombosis (ST) compared to non-diabetic patients. METHODS: In 126 centers worldwide 3067 patients were enrolled in the NOBORI 2 registry, 888 patients suffered from diabetes mellitus (DM), 213 of them (14%) being insulin dependent (IDDM)...
February 10, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28178976/advanced-glycation-end-products-induce-brain-derived-neurotrophic-factor-release-from-human-platelets-through-the-src-family-kinase-activation
#20
Kazuo Furukawa, Ichiro Fuse, Yuriko Iwakura, Hidekazu Sotoyama, Osamu Hanyu, Hiroyuki Nawa, Hirohito Sone, Nobuyuki Takei
BACKGROUND: Brain-derived neurotrophic factor (BDNF) exerts beneficial effects not only on diabetic neuropathies but also on cardiovascular injury. There is argument regarding the levels of serum BDNF in patients with diabetes mellitus (DM). Because BDNF in peripheral blood is rich in platelets, this may represent dysregulation of BDNF release from platelets. Here we focused on advanced glycation end products (AGEs), which are elevated in patients with DM and have adverse effects on cardiovascular functions...
February 8, 2017: Cardiovascular Diabetology
journal
journal
40195
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"